Limits...
Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma.

Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C, Celada-Alvarez FJ, de Unamuno-Bustos B, Llavador-Ros M, Ballesta-Cuñat A, Barker CA, Tormo-Mico A, Botella-Estrada R, Perez-Calatayud J - J Contemp Brachytherapy (2015)

Bottom Line: Cosmesis was excellent, with more than 60% of cases without skin alteration and with subtle changes in the rest.It could be a good choice for elderly patients, patients with contraindications for surgery (due to comorbidities or anticoagulant drugs) or patients where surgery would result in a more disfiguring outcome.A longer follow-up and more studies are needed to confirm these preliminary results.

View Article: PubMed Central - PubMed

Affiliation: Dermatology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.

ABSTRACT

Purpose: Surface electronic brachytherapy (EBT) is an alternative radiotherapy solution to external beam electron radiotherapy and high-dose-rate radionuclide-based brachytherapy. In fact, it is also an alternative solution to surgery for a subgroup of patients. The objective of this work is to confirm the clinical efficacy, toxicity and cosmesis of a new EBT system, namely Esteya(®) in the treatment of nodular and superficial basal cell carcinoma (BCC).

Material and methods: This is a prospective single-center, non-randomized pilot study to assess the efficacy and safety of EBT in nodular and superficial BCC using the Esteya(®) system. The study was conducted from June 2014 to February 2015. The follow up time was 6 months for all cases.

Results: Twenty patients with 23 lesions were included. A complete response was documented in all lesions (100%). A low level of toxicity was observed after the 4(th) fraction in all cases. Erythema was the most frequent adverse event. Cosmesis was excellent, with more than 60% of cases without skin alteration and with subtle changes in the rest.

Conclusions: Electronic brachytherapy with Esteya(®) appears to be an effective, simple, safe, and comfortable treatment for nodular and superficial BCC associated with excellent cosmesis. It could be a good choice for elderly patients, patients with contraindications for surgery (due to comorbidities or anticoagulant drugs) or patients where surgery would result in a more disfiguring outcome. A longer follow-up and more studies are needed to confirm these preliminary results.

No MeSH data available.


Related in: MedlinePlus

A) Superficial basal cell carcinoma located on the cheek prior to treatment. B) Two weeks after last EBT fraction. C) Three months after last EBT fraction. D) Six months after last EBT fraction
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499517&req=5

Figure 0004: A) Superficial basal cell carcinoma located on the cheek prior to treatment. B) Two weeks after last EBT fraction. C) Three months after last EBT fraction. D) Six months after last EBT fraction

Mentions: A complete response was documented for all lesions (100%). We took clinical and dermoscopic photographs at 2 weeks, 6 weeks, 3 months, and 6 months after treatment (see Figs. 3 and 4). A punch biopsy was planned at 6 months if there was suspicion of residual disease, but this has not occurred. Minimum follow-up was 6 months.


Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma.

Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C, Celada-Alvarez FJ, de Unamuno-Bustos B, Llavador-Ros M, Ballesta-Cuñat A, Barker CA, Tormo-Mico A, Botella-Estrada R, Perez-Calatayud J - J Contemp Brachytherapy (2015)

A) Superficial basal cell carcinoma located on the cheek prior to treatment. B) Two weeks after last EBT fraction. C) Three months after last EBT fraction. D) Six months after last EBT fraction
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499517&req=5

Figure 0004: A) Superficial basal cell carcinoma located on the cheek prior to treatment. B) Two weeks after last EBT fraction. C) Three months after last EBT fraction. D) Six months after last EBT fraction
Mentions: A complete response was documented for all lesions (100%). We took clinical and dermoscopic photographs at 2 weeks, 6 weeks, 3 months, and 6 months after treatment (see Figs. 3 and 4). A punch biopsy was planned at 6 months if there was suspicion of residual disease, but this has not occurred. Minimum follow-up was 6 months.

Bottom Line: Cosmesis was excellent, with more than 60% of cases without skin alteration and with subtle changes in the rest.It could be a good choice for elderly patients, patients with contraindications for surgery (due to comorbidities or anticoagulant drugs) or patients where surgery would result in a more disfiguring outcome.A longer follow-up and more studies are needed to confirm these preliminary results.

View Article: PubMed Central - PubMed

Affiliation: Dermatology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.

ABSTRACT

Purpose: Surface electronic brachytherapy (EBT) is an alternative radiotherapy solution to external beam electron radiotherapy and high-dose-rate radionuclide-based brachytherapy. In fact, it is also an alternative solution to surgery for a subgroup of patients. The objective of this work is to confirm the clinical efficacy, toxicity and cosmesis of a new EBT system, namely Esteya(®) in the treatment of nodular and superficial basal cell carcinoma (BCC).

Material and methods: This is a prospective single-center, non-randomized pilot study to assess the efficacy and safety of EBT in nodular and superficial BCC using the Esteya(®) system. The study was conducted from June 2014 to February 2015. The follow up time was 6 months for all cases.

Results: Twenty patients with 23 lesions were included. A complete response was documented in all lesions (100%). A low level of toxicity was observed after the 4(th) fraction in all cases. Erythema was the most frequent adverse event. Cosmesis was excellent, with more than 60% of cases without skin alteration and with subtle changes in the rest.

Conclusions: Electronic brachytherapy with Esteya(®) appears to be an effective, simple, safe, and comfortable treatment for nodular and superficial BCC associated with excellent cosmesis. It could be a good choice for elderly patients, patients with contraindications for surgery (due to comorbidities or anticoagulant drugs) or patients where surgery would result in a more disfiguring outcome. A longer follow-up and more studies are needed to confirm these preliminary results.

No MeSH data available.


Related in: MedlinePlus